Galmed Pharma Annual Meeting Adjourned Due to Lack of Quorum

Ticker: GLMD · Form: 6-K · Filed: Jul 11, 2024 · CIK: 1595353

Galmed Pharmaceuticals LTD. 6-K Filing Summary
FieldDetail
CompanyGalmed Pharmaceuticals LTD. (GLMD)
Form Type6-K
Filed DateJul 11, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: meeting-adjournment, shareholder-meeting, corporate-governance

TL;DR

Galmed Pharma's shareholder meeting postponed to July 17th due to no-shows.

AI Summary

Galmed Pharmaceuticals Ltd. convened its Annual General Meeting of Shareholders on July 10, 2024, but it was adjourned for one week due to a lack of quorum. The meeting will now reconvene on Wednesday, July 17, 2024, at 16:00 p.m. Israel time at the offices of Meitar Law Offices in Ramat Gan.

Why It Matters

The adjournment of the annual meeting may indicate shareholder engagement issues or concerns that could impact future corporate decisions or governance.

Risk Assessment

Risk Level: low — The filing is a procedural update regarding a meeting adjournment and does not contain material financial or operational news.

Key Numbers

Key Players & Entities

FAQ

Why was the Annual General Meeting adjourned?

The meeting was adjourned due to a lack of quorum.

When will the Annual General Meeting reconvene?

The meeting will reconvene on Wednesday, July 17, 2024.

What time will the reconvened meeting take place?

The meeting will take place at 16:00 p.m. Israel time.

Where will the reconvened meeting be held?

The meeting will be held at the offices of Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

What is the company's primary business?

Galmed Pharmaceuticals Ltd. is in the Pharmaceutical Preparations industry (SIC code 2834).

Filing Stats: 293 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-07-11 08:50:53

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: July 11, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing